1st Quarter - Report

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$660,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues regarding expanding the availability of the charitable deduction for non-itemizers and issues respecting charitable giving and life income planning and issues respecting the medical expense deduction.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: White House Office; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Environmental Protection Agency (EPA); Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE; U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA)

Health Issues HCR

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, and wellness, including: HR 1010, to provide that the short-term rule has no force or effect; HR 986 & S 466, Protecting Americans with Pre-Existing Conditions Act; HR 1425, State Health Care Premium Reduction Act; HR 1386, Expand Navigators Resources for Outreach, Learning, and Longevity Act of 2019; HR 1884, Protecting Pre-Existing Conditions & Making Health Care More Affordable Act of 2019; HR 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019; Issues relating to curbing health care costs; Issues related to surprise medical billing; H.R.647, the Palliative Care and Hospice Education and Training Act; Issues related to Breast Density and Mammography Reporting; H.R.820 & S.292, the Childhood Cancer STAR Act; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017; Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; Caregiving, including H.R. 3759/S. 1028, the RAISE Family Caregivers Act; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; and H.R. 1730 and S. 741, the Cancer Drug Parity Act.

Contacted: U.S. Agency for International Development (USAID); White House Office; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Labor, Dept of (DOL); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Natl Institutes of Health (NIH); State, Dept of (DOS)

Bills named: H.R. 3759 (116th), H.R. 647 (116th), H.R. 1730 (116th), H.R. 1425 (116th), S. 2358 (116th), S. 292 (116th), H.R. 986 (116th), H.R. 820 (116th), H.R. 1884 (116th), S. 204 (116th), H.R. 2222 (116th), H.R. 1010 (116th), S. 741 (116th), H.R. 987 (116th), H.R. 878 (116th), H.R. 1386 (116th), S. 1028 (116th), S. 1107 (116th), H.R. 4897 (116th), S. 1719 (116th), H.R. 1966 (116th), H.R. 1409 (116th), H.Res. 282 (116th), H.R. 1028 (116th)

Medicare/Medicaid MMM

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; States Achieve Medicaid Expansion (SAME) Act, S. 585, to ensure states receive the same matching funds regardless of when they expand their Medicaid program; Lymphedema Treatment Act, HR 1948, on Medicare reimbursement for supplies needed by lymphedema patients; CMS-issued regulations pertaining to Medicare Part B reimbursement; Draft legislation on establishment of Medicaid reimbursement for patient navigation; Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; Issues related to Medicare coverage for BCRA testing and preventive surgery; Issues related to utilization management in Medicare Part D plans; Potential legislation for lowering prescription drug costs and lowering out of pocket costs for Medicare beneficiaries; and CMS proposed regulatory changes on the six protected classes policy within the Medicare Part D prescription drug benefit.

Contacted: Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); White House Office; U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Environmental Protection Agency (EPA); SENATE; Veterans Affairs, Dept of (VA)

Bills named: S. 668 (116th), H.R. 1570 (116th), S. 585 (116th), H.R. 1948 (116th)

Budget/Appropriations BUD

FY 2019 and FY 2020 federal appropriations for: The Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the State/Foreign Operations Appropriations Act; issues relating to global health funding for HPV vaccination and cervical cancer screening and treatment; and, issues regarding future work and funding of the CDC tobacco work. FY 2020 federal appropriations for: cancer research and prevention funding at the NIH, NCI and CDC.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Centers For Disease Control & Prevention (CDC); U.S. Trade Representative (USTR); Veterans Affairs, Dept of (VA); Labor, Dept of (DOL); State, Dept of (DOS)

Tobacco TOB

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019; H.R. 2111 and S. 1048, The Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act, and issues regarding age of sale of tobacco products; Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation; Issues related to tobacco taxes, flavored tobacco products, and online sale of tobacco products, H.R. 293, Youth Vaping Prevention Act of 2019; and Issues related to smoke-free policies for the Veterans Health Administration.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); Environmental Protection Agency (EPA); Veterans Affairs, Dept of (VA); SENATE; U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); White House Office; State, Dept of (DOS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 293 (116th), H.R. 1854 (116th), H.R. 2111 (116th), S. 1048 (116th), S. 9 (116th), H.R. 2084 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.